Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those posters are undoubtedly right. Why are you suggesting otherwise bagholder?
Not only tested but discussed here daily. Even more fascinating is the ubiquitous effort by so many posters to convince you it's dead. 🙄
Had you simply bought at .000001 and sold at .0013 you could be a billionaire. Why aren’t more people doing this?
Stoped by to see what was going on here. Spend $6.95 to buy $1.00 looks like a lotto purchase . No one has seen or spoken with LE or any of his friends, this chat is all hope with all kinds of speculations…
Has anyone sent a certified letter to the office or Leo’s home? Signature will prove he is alive.
Fascinating how a supposed dead drug is still being tested. Perhaps we will see a miraculous offer.
This from the Nature article: "Brilacidin alone was shown to inhibit the growth of C. neoformans, acting as a fungicidal drug, but surprisingly also potentiated the activity of caspofungin (CAS) against this species. We investigated the mechanism of action of BRI and BRI + CAS against C. neoformans. We propose BRI as a new antifungal agent against cryptococcosis." You better believe that there are now plenty of eyeballs alert to this amazing drug. One of the big-boy pharma companies will snatch it up without a doubt. It will only get more expensive as time goes by.
Someone purchase 1 millions shares for $1.....was that you Mr. Loan?????
What a disaster. Maybe Frenchfraud managed to unload a few shares...
Too sad. If B had any value, the snake would have done something by now. You are confusing hope with reality. Time to get real. It is game over.
Walking days are over. If one were to touch this disaster, its corpse would turn to dust.
Odd volume considering it's almost impossible to buy/sell right now.
Price 0.000001 -0.000999 (-99.90%)
LMAO!
first trade of the day a million shares--if only...
Really does sounds like story time (again)
Because there’s no way she strong armed Leo to get on the phone and reveal this sort of info! Leo is acting unethical in the way he is handling this and something does really stink in Kentucky but I’m just saying the poster is full of shit!
“Shady, unethical people do shady, unethical shit.”
Pot lickers know.
What’s stupid about it? Shady, unethical people do shady, unethical shit.
Ok. Thank you.
Running girl is full of shiz, and I’m sure this is who wrote this ridiculous post! Things are bad enough without people making up stupid shit like this
Leo should pay the judgement out of his own pocket since it was his F up!!!!!!!!
I think that that info is detrimental to someone divulging it. Get proof.
They knew about that BS years ago
When will we hear good news that will turn this ship around?
Eli Lilly just paid $3.2B for a drug being evaluated in two Phase 2 studies that has the "potential" to improve outcomes in treatment of IBD:
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Lilly will commence a tender offer to acquire all outstanding shares of Morphic for a purchase price of $57 per share in cash (an aggregate of approximately $3.2 billion) payable at closing. The transaction has been approved by the boards of directors of both companies.
Morphic's lead program is a selective oral small molecule inhibitor of a4ß7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcerative colitis and one Phase 2 study in Crohn's disease. Additionally, Morphic is developing a preclinical pipeline of other molecules for the treatment of autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
https://www.prnewswire.com/news-releases/lilly-to-acquire-morphic-to-improve-outcomes-for-patients-with-inflammatory-bowel-disease-302190489.html
Along with Lilly, other drugmakers such as Abbvie Inc (ABBV.N), Pfizer (PFE.N), and Johnson & Johnson (JNJ.N), are also jostling for a share of the bowel disease market.
https://www.reuters.com/markets/deals/eli-lilly-acquire-morphic-holding-32-billion-2024-07-08/
Brilacidin has "potential" in this space:
https://www.biospace.com/article/releases/innovation-pharmaceuticals-provides-update-on-u-s-patent-applications-covering-use-of-brilacidin-in-inflammatory-bowel-diseases-coronaviruses-and-fungal-diseases/
This should quickly patch things up between Leo and Gill. "Busting Cryptococcus with Brilacidin" written by the senior editor of Research Highlights.
This journal has a 2023 impact factor of 69.2, ranking it 1st out of 135 journals in the "Microbiology" category.
Extreme credibility vs. anonymous banned poster. Obviously huge value here that can not and will not be ignored given the massive humanitarian worldwide need.
THANK YOU, SitTight!
Wow nice to see SitTight. Nature is a highly regarded journal. I'm liking their recent Bril+Caspofungin patent application.
Can't....and wouldn't if I could.
Apparently we don't "all know and understand how this works."
Moderators can't ban anyone.
LoanRanger if you want to say hi to her why don't you take her off ignore so she can PM you during Happy Hour?
Sounds like you are scared of her just like TheHound/Zandant and others are.
Seems like you have a lot of friends who like to tell stories.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174476424
New Nature article: "Busting Cryptococcus with brilacidin". Even better, it is featured as "Research Highlight" and was written by its senior editor!
https://www.nature.com/articles/s41579-024-01081-7
It highlights this recent paper published in mBio: "Brilacidin, a novel antifungal agent against Cryptococcus neoformans".
https://pubmed.ncbi.nlm.nih.gov/38916308/
This new Nature article came out today and is published under "Research Highlight" in "Nature Reviews Microbiology". According to the Journal Citation Reports, the journal has a 2023 impact factor of 69.2, ranking it 1st out of 135 journals in the "Microbiology" category.
This should throw an even bigger spotlight on the importantance of Brilacidin as new and best tool against Cryptococcus neoformans, the top-ranked fungal pathogen, and others.
Why don't you remove her ban so you can say hello to her.....
Please say hello to runninggirl for me the next time you guys chat.
Did the banned poster ask him if he and Jane are still taking a salary????
“Banned poster”
I’m skeptical. Too many holes in this story.
I’m leaving it at that for now.
Ok now I know for sure this is a parody account.
Hahahaha. This whole thing is all planned you fool.
What doesn't ring true to me is that rather than go bankrupt, Leo has enough financial resources that if he loses in court he could loan IPIX the money and pay up and eliminate that issue so that the IPIX.BeaMed alliance can move forward. Leo would quickly recoup his money via salary and profits and repayment of the loan.. imo.
Bankruptcy and the formal end of IPIX sound about right.
From a banned poster
I finally talked to Leo.
I called Leo's home phone all day Thursday because I knew he would be home and his son finally answered it with a freaking attitude. I threatened and cursed his little ass out and had him put Leo on the phone or I threatened to have his phone ringing all night and day long from various investors.
Incredibly and I'm sure reluctantly Leo answered the phone when he found out it was me. What he told me was rather disturbing.
Apparently He and Gil had a falling out and now Gil is waiting for the result of the Cummings appeal.
Gil told Leo why should he file for a 510(k) on his laser and give Leo 35% of the profits when if Leo loses(which Gil thinks he will) will be forced in to Bankruptcy and IPIX will no longer exist and BeaMed can keep 100% of the profits.
Leo apologized up and down for the way things have turned out but I just said fuck you and your family. We will see you in court and hung up.
Sorry. Thanks.
Hey Frenchy, any word from Leo????? When will he address his shareholders???? His silence is just not right!!!!!
Where’s the stinkin laser! Come on leo
Follow LR post history.
He's making a big splash there! Lol
He didn't thank me for giving him a new board to post on.
In the fertile imaginations of the broke and deluded.
Where can we find IPIX 2.0???????
Followers
|
976
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
403557
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |